Newsfeeds - Spark Newswire

1 minute read

Eton Pharmaceuticals And ANI Pharmaceuticals Announce Commercial Availability Of Carglumic Acid Tablets, The First And Only FDA-Approved Generic Version Of Carbaglu

Today, 3:59 AM

Product is now available exclusively through Anovo specialty pharmacy Product is stable at room temperature while Carbaglu® requires refrigeration Eton Cares patient support program will

ANIP

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline

Today, 3:59 AM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

1 minute read

FDA Approves Eton’s Formulated Topiramate For Seizure, Migraine Treatment

By Vandana Singh

Today, 3:59 AM

â€‹â€‹â€‹â€‹â€‹â€‹Eton Pharmaceuticals Inc (NASDAQ:ETON) and Azurity Pharmaceuticals Inc have announced that the FDA has approved Eprontia (topiramate) oral solution, 25mg/mL. Eprontia has…

ETON

5 minute read

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates

By Shanthi Rexaline

Today, 3:59 AM

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.

AADI

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 3:59 AM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT

2 minute read

Earnings

How Bad Are Eton Pharmaceuticals’s Earnings? | Return On Capital Employed

By Benzinga Insights

Today, 3:59 AM

Eton Pharmaceuticals (NASDAQ:ETON) brought in sales totaling $3.07 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 143.35%, resulting in a loss of $2.33 million.

ETON